Abstract: A strain sensor may have a conductive elastic yarn including a first fiber having a predetermined length and a shape of a fiber yarn and a second fiber having electrical conductivity and a sheet shape. The strain sensor may have a pair of wiring members electrically connected to both ends of the conductive elastic yarn. The conductive elastic yarn, with the second fiber wrapped around the first fiber, is twisted in a coil shape.

Abstract: The present disclosure relates to an exhaust pipe apparatus. The exhaust pipe apparatus includes a first exhaust pipe provided to directly discharge exhaust gas discharged from a combustion engine to the outside, a second exhaust pipe connected in parallel with the first exhaust pipe and having a branch pipe connected to one side thereof such that the exhaust gas is directly discharged to the outside or discharged through the branch pipe, and a first damper installed in the second exhaust pipe to control a flow of the exhaust gas to be directly discharged to the outside or discharged through the branch pipe.

Abstract: The present disclosure relates to an exhaust pipe apparatus. The exhaust pipe apparatus includes a first exhaust pipe provided to directly discharge exhaust gas discharged from a combustion engine to the outside, a second exhaust pipe connected in parallel with the first exhaust pipe and having a branch pipe connected to one side thereof such that the exhaust gas is directly discharged to the outside or discharged through the branch pipe, and a first damper installed in the second exhaust pipe to control a flow of the exhaust gas to be directly discharged to the outside or discharged through the branch pipe.

Abstract: The present invention relates to a substituted piperidines represented by following Chemical Formula 1, which have a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same: wherein A, B, and X are defined therein.

Abstract: The present invention relates to a novel compound having a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic action and an effect on pancreatic beta cells, and also improves lipid metabolism which is a chronic cardiovascular risk factor, thereby having a treatment and/or prevention effect of a metabolic disease such as diabetes.

Abstract: The present invention relates to a composition for preventing or treating renal diseases. The composition of the present invention improves lipid metabolism, prevents histological damage including renal fibrosis, alleviates microalbuminuria, and maintains nephrons of renal glomeruli. Therefore, the composition is useful for treating renal diseases.

Abstract: A waste heat recovery device for a marine vessel is disclosed. According to the embodiments of the present invention, the waste heat recovery device for a marine vessel includes: a heat exchanger, which recovers heat from the exhaust fumes discharged from the engine, to heat a first refrigerant under uniform pressure; a turbine which is driven by adiabatically expanding the first refrigerant heated under uniform pressure; a condenser which condenses the adiabatically expanded first refrigerant; and a heat exchanging pump which compresses the condensed first refrigerant so as to re-circulate the compressed first refrigerant to the heat exchanger.

Abstract: The present invention relates to a composition for preventing or treating renal diseases. The composition of the present invention improves lipid metabolism, prevents histological damage including renal fibrosis, alleviates microalbuminuria, and maintains nephrons of renal glomeruli. Therefore, the composition is useful for treating renal diseases.

Abstract: A waste heat recovery device for a marine vessel is disclosed. According to the embodiments of the present invention, the waste heat recovery device for a marine vessel includes: a heat exchanger, which recovers heat from the exhaust fumes discharged from the engine, to heat a first refrigerant under uniform pressure; a turbine which is driven by adiabatically expanding the first refrigerant heated under uniform pressure; a condenser which condenses the adiabatically expanded first refrigerant; and a heat exchanging pump which compresses the condensed first refrigerant so as to re-circulate the compressed first refrigerant to the heat exchanger.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.

Abstract: The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof. Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.

Abstract: The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and bioavailability and therefore can be useful for the prophylaxis or treatment of DPP-IV-related diseases such as diabetes or obesity.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.

Abstract: The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and bioavailability and therefore can be useful for the prophylaxis or treatment of DPP-IV-related diseases such as diabetes or obesity.

Abstract: The present invention provides a novel phenylpropionic acid derivative and a PPAR-? modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-? and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

Abstract: Provided are 1-phenylpiperidin-3-one derivatives and pharmaceutically acceptable salts thereof, having cysteine protease inhibitory activity, pharmaceutical compositions containing the same as an active ingredient, and processes for the preparation thereof.